ProGenTech gains $21M in third venture round
ProGenTech, with operations in California and China, has pocketed $21 million in its third round of venture financing. The biotech company markets products for research and medical diagnostics and is developing a contamination free, cassette based automated nucleic acid purification system. Bay City Capital and DT Capital led the round. ProGenTech was founded by two engineers: Steve Yu and Jesus Ching. Yu will remain a director of the company and become its president and COO. Ching will become the chief scientific officer of ProGenTech.
- check out the press release
Be the first to comment
More stories about China
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
